These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 23486421)

  • 21. Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.
    Békássy ZD; Kristoffersson AC; Cronqvist M; Roumenina LT; Rybkine T; Vergoz L; Hue C; Fremeaux-Bacchi V; Karpman D
    Nephrol Dial Transplant; 2013 Nov; 28(11):2899-907. PubMed ID: 24009284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
    Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M; Emma F
    Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
    Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence.
    Keenswijk W; Raes A; Vande Walle J
    Eur J Pediatr; 2018 Mar; 177(3):311-318. PubMed ID: 29288280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
    Verhave JC; Wetzels JF; van de Kar NC
    Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv131-41. PubMed ID: 25165180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
    Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
    Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?
    Gilbert RD; Nagra A; Haq MR
    Med Hypotheses; 2013 Sep; 81(3):400-3. PubMed ID: 23786906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa L; Espinosa M; Grinyó JM; Macía M; Mendizábal S; Praga M; Román E; Torra R; Valdés F; Vilalta R; Rodríguez de Córdoba S
    Nefrologia; 2015; 35(5):421-47. PubMed ID: 26456110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults.
    Derad I; Obermann B; Katalinic A; Eisemann N; Knobloch JK; Sayk F; Wellhöner P; Lehnert H; Solbach W; Süfke S; Steinhoff J; Nitschke M
    Nephrol Dial Transplant; 2016 Jan; 31(1):95-103. PubMed ID: 26180049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
    Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W
    Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
    Zuber J; Frimat M; Caillard S; Kamar N; Gatault P; Petitprez F; Couzi L; Jourde-Chiche N; Chatelet V; Gaisne R; Bertrand D; Bamoulid J; Louis M; Sberro Soussan R; Navarro D; Westeel PF; Frimat L; Colosio C; Thierry A; Rivalan J; Albano L; Arzouk N; Cornec-Le Gall E; Claisse G; Elias M; El Karoui K; Chauvet S; Coindre JP; Rerolle JP; Tricot L; Sayegh J; Garrouste C; Charasse C; Delmas Y; Massy Z; Hourmant M; Servais A; Loirat C; Fakhouri F; Pouteil-Noble C; Peraldi MN; Legendre C; Rondeau E; Le Quintrec M; Frémeaux-Bacchi V
    J Am Soc Nephrol; 2019 Dec; 30(12):2449-2463. PubMed ID: 31575699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eculizumab in Pediatric Dense Deposit Disease.
    Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Posttransplant recurrence of atypical hemolytic uremic syndrome.
    Valoti E; Alberti M; Noris M
    J Nephrol; 2012; 25(6):911-7. PubMed ID: 22760880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation.
    Carr R; Cataland SR
    Ann Hematol; 2013 Jun; 92(6):845-6. PubMed ID: 23154867
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.